Mission Wealth Management LP Buys 1,379 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mission Wealth Management LP grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 292.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,850 shares of the biopharmaceutical company’s stock after purchasing an additional 1,379 shares during the quarter. Mission Wealth Management LP’s holdings in Regeneron Pharmaceuticals were worth $1,780,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of REGN. Hartline Investment Corp acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $1,163,000. Norden Group LLC grew its stake in Regeneron Pharmaceuticals by 48.1% during the first quarter. Norden Group LLC now owns 388 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 126 shares in the last quarter. Dillon & Associates Inc. grew its stake in Regeneron Pharmaceuticals by 4.9% during the first quarter. Dillon & Associates Inc. now owns 12,368 shares of the biopharmaceutical company’s stock worth $11,898,000 after buying an additional 573 shares in the last quarter. HB Wealth Management LLC grew its stake in Regeneron Pharmaceuticals by 49.3% during the first quarter. HB Wealth Management LLC now owns 1,671 shares of the biopharmaceutical company’s stock worth $1,608,000 after buying an additional 552 shares in the last quarter. Finally, Concord Wealth Partners grew its stake in Regeneron Pharmaceuticals by 10.2% during the first quarter. Concord Wealth Partners now owns 530 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 49 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders have sold 63,208 shares of company stock valued at $62,514,142 in the last three months. 7.48% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on REGN shares. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. UBS Group raised their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Monday, June 17th. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target on the stock. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,027.55.

Regeneron Pharmaceuticals Stock Up 1.0 %

NASDAQ REGN traded up $10.14 during mid-day trading on Friday, hitting $1,034.23. The company’s stock had a trading volume of 418,302 shares, compared to its average volume of 436,890. The company’s 50 day simple moving average is $998.19 and its 200 day simple moving average is $956.36. Regeneron Pharmaceuticals, Inc. has a twelve month low of $688.52 and a twelve month high of $1,081.17. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $113.96 billion, a price-to-earnings ratio of 30.55, a PEG ratio of 2.12 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.